Literature DB >> 27809521

Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue.

Jehad Almaliti1,2, Ayad A Al-Hamashi1, Ahmed T Negmeldin3, Christin L Hanigan4, Lalith Perera5, Mary Kay H Pflum3, Robert A Casero4, L M Viranga Tillekeratne1.   

Abstract

A number of analogues of the marine-derived histone deacetylase inhibitor largazole incorporating major structural changes in the depsipeptide ring were synthesized. Replacing the thiazole-thiazoline fragment of largazole with a bipyridine group gave analogue 7 with potent cell growth inhibitory activity and an activity profile similar to that of largazole, suggesting that conformational change accompanying switching hybridization from sp3 to sp2 at C-7 is well tolerated. Analogue 7 was more class I selective compared to largazole, with at least 464-fold selectivity for class I HDAC proteins over class II HDAC6 compared to a 22-fold selectivity observed with largazole. To our knowledge 7 represents the first example of a potent and highly cytotoxic largazole analogue not containing a thiazoline ring. The elimination of a chiral center derived from the unnatural amino acid R-α-methylcysteine makes the molecule more amenable to chemical synthesis, and coupled with its increased class I selectivity, 7 could serve as a new lead compound for developing selective largazole analogues.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27809521      PMCID: PMC5574184          DOI: 10.1021/acs.jmedchem.6b01271

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  50 in total

1.  Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability.

Authors:  Hanae Benelkebir; Sabrina Marie; Annette L Hayden; Jason Lyle; Paul M Loadman; Simon J Crabb; Graham Packham; A Ganesan
Journal:  Bioorg Med Chem       Date:  2011-02-17       Impact factor: 3.641

Review 2.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 3.  Current therapeutic strategies for multiple myeloma.

Authors:  Yoshihiro Torimoto; Motohiro Shindo; Katsuya Ikuta; Yutaka Kohgo
Journal:  Int J Clin Oncol       Date:  2015-04-09       Impact factor: 3.402

Review 4.  Romidepsin: a novel histone deacetylase inhibitor for cancer.

Authors:  Erin M Bertino; Gregory A Otterson
Journal:  Expert Opin Investig Drugs       Date:  2011-06-24       Impact factor: 6.206

5.  Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.

Authors:  José A Souto; Esther Vaz; Ilaria Lepore; Ann-Christin Pöppler; Gianluigi Franci; Rosana Alvarez; Lucia Altucci; Angel R de Lera
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

6.  Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.

Authors:  Yongcheng Ying; Kanchan Taori; Hyoungsu Kim; Jiyong Hong; Hendrik Luesch
Journal:  J Am Chem Soc       Date:  2008-05-29       Impact factor: 15.419

Review 7.  Histone deacetylase inhibitors and cell death.

Authors:  Jing Zhang; Qing Zhong
Journal:  Cell Mol Life Sci       Date:  2014-06-05       Impact factor: 9.261

8.  Largazole, a class I histone deacetylase inhibitor, enhances TNF-α-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts.

Authors:  Salahuddin Ahmed; Sharayah Riegsecker; Maria Beamer; Ayesha Rahman; Joseph V Bellini; Pravin Bhansali; L M Viranga Tillekeratne
Journal:  Toxicol Appl Pharmacol       Date:  2013-04-28       Impact factor: 4.219

9.  Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization.

Authors:  Hongyan Zhou; Sheng Jiang; Jianping Chen; Xiangrong Ren; Jiayi Jin; Shao Bo Su
Journal:  Eur J Pharmacol       Date:  2014-06-26       Impact factor: 4.432

10.  Evaluation of class I HDAC isoform selectivity of largazole analogues.

Authors:  Bumki Kim; Heekwang Park; Lilibeth A Salvador; Patrick E Serrano; Jason C Kwan; Sabrina L Zeller; Qi-Yin Chen; Soyoung Ryu; Yanxia Liu; Seongrim Byeon; Hendrik Luesch; Jiyong Hong
Journal:  Bioorg Med Chem Lett       Date:  2014-07-09       Impact factor: 2.823

View more
  5 in total

1.  Synthesis and biological evaluation of largazole zinc-binding group analogs.

Authors:  Bumki Kim; Ranjala Ratnayake; Hyunji Lee; Guqin Shi; Sabrina L Zeller; Chenglong Li; Hendrik Luesch; Jiyong Hong
Journal:  Bioorg Med Chem       Date:  2017-04-04       Impact factor: 3.641

2.  A new class of cytotoxic agents targets tubulin and disrupts microtubule dynamics.

Authors:  Ayad A Al-Hamashi; Radhika Koranne; Samkeliso Dlamini; Abdulateef Alqahtani; Endri Karaj; Maisha S Rashid; Joseph R Knoff; Matthew Dunworth; Mary Kay H Pflum; Robert A Casero; Lalith Perera; William R Taylor; L M Viranga Tillekeratne
Journal:  Bioorg Chem       Date:  2021-08-30       Impact factor: 5.275

Review 3.  Marine Cyanobacteria: A Source of Lead Compounds and their Clinically-Relevant Molecular Targets.

Authors:  Lik Tong Tan; Ma Yadanar Phyo
Journal:  Molecules       Date:  2020-05-08       Impact factor: 4.411

Review 4.  Impact of Cross-Coupling Reactions in Drug Discovery and Development.

Authors:  Melissa J Buskes; Maria-Jesus Blanco
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

Review 5.  Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms.

Authors:  Lichuan Wu; Ke Ye; Sheng Jiang; Guangbiao Zhou
Journal:  Mar Drugs       Date:  2021-08-27       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.